- Companies
- Oviva
Oviva Funding, Investors & Competitors
Oviva has raised $350M across 4 funding rounds, most recently a $237M Series D in January 2026.
About Oviva
Oviva is an Altendorf-headquartered digital health company delivering app-based programs for type 2 diabetes and obesity management across Europe. Launched in 2013, it partners with the UK's National Health Service to treat over 50,000 patients via personalized coaching from registered dietitians using its platform combining smartphone apps, web portals, and connected devices like scales and glucose monitors. Oviva operates clinics in Zurich, London, and Berlin, demonstrating clinical outcomes such as average 7 kg weight loss and HbA1c reductions while cutting healthcare costs through remote delivery.
Founded
2013
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Subscription
Oviva Funding History
Oviva has raised a total of $350M across 4 funding rounds, plus 1 secondary share sale.
Oviva's first fundraising round was a $12M Series A in November 2017. The most recent completed round was a $237M Series D in January 2026.
Oviva funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Jan 2026 | Secondary | Kinnevik (lead); EGS Beteiligungen; Norrsken VC; Planet First Partners; Sofina; Lunate; A.P. Moller Holding | - | Oviva is Europe's leading provider of AI-enabled digital care for weight-related and chronic conditions, including obesity, hypertension, and type 2 diabetes. The company has supported over one million patients, validated its approach through more than 90 peer-reviewed studies, and tripled new patient intake over the past two years. Oviva achieved cash-flow profitability in 2025 and is nationally reimbursed in the U.K., Germany, and Switzerland. Kinnevik led Oviva's USD 220m Series D financing round with a USD 100m investment through primary and secondary capital, becoming the largest shareholder with a 13% ownership stake. The round, which closed around January 22, 2026, included participation from investors such as Sofina and Temasek, alongside existing backers. The funds will support expansion into additional markets and chronic conditions, as well as AI initiatives to meet growing demand. In Kinnevik's Q4 2026 earnings call, Oviva was valued at a multiple of 1.1x its $1.5 billion ARR as of year-end 2025. Oviva operates in a market addressing over 200 million adults with obesity and weight-related conditions in Europe, where healthcare systems face clinician shortages and limited in-person care access. |
| Jan 2026 | Series D | Kinnevik (lead); EGS Beteiligungen; Norrsken VC; Planet First Partners; Sofina; Lunate; A.P. Moller Holding | $237M | Oviva is a European digital health company focused on weight-related and chronic conditions, founded in 2014 by Kai Eberhardt (CEO), Manuel Baumann (CTO), and Mark Jenkins. The company's platform connects patients with multidisciplinary care teams and uses AI to personalize support, with programs offered free to patients in its core markets—Germany, the UK, and Switzerland—through full reimbursement coverage. Oviva has supported over one million patients to date, with more than 90 peer-reviewed studies validating its programs' effectiveness. In January 2026, Oviva raised USD 220 million in Series D funding led by Kinnevik, which invested USD 100 million and became the company's largest shareholder with a 13 percent ownership stake. Other investors in the round included existing backers Temasek and Sofina, alongside new investors Planet First Partners, A.P. Moller Holding, Lunate, EGS Beteiligungen AG, and Norrsken VC. Over the past two years, Oviva tripled new patient intake and achieved cash-flow profitability in 2025, demonstrating the scalability of its business model. The funding will support Oviva's expansion into new markets and additional chronic conditions such as hypertension and type 2 diabetes, as well as further advancement of its AI-driven platform. |
| Aug 2021 | Series C | Sofina (lead); Temasek (lead); MTIP AG; F-Prime; Eight Roads Ventures; AlbionVC; Earlybird VC | $80M | Oviva is a London-based digital health startup founded in 2014 that provides diet and lifestyle coaching through a combination of certified dietitian support and mobile app technology. The company's software solution helps people manage diet-related habits to improve long-term health, with a focus on conditions like Type 2 diabetes and weight-related chronic illnesses. Oviva works with over 5,000 partnerships including health systems, insurers, and doctors across Europe, with operations in the United Kingdom, Germany, Switzerland, and France, including availability through the UK's NHS. In August/September 2021, Oviva closed an $80 million Series C funding round co-led by Sofina and Temasek, with participation from existing investors AlbionVC, Earlybird Venture Capital, Eight Roads Ventures, F-Prime Capital, MTIP AG, and several angel investors, bringing total capital raised to approximately $115–117 million. The funding was intended to scale operations into new European markets through both organic growth and potential M&A, leveraging Oviva's proven product-market fit and partnerships with major health systems. |
| Jan 2020 | Series B | MTIP AG (lead); Partech; F-Prime; Eight Roads Ventures; AlbionVC; Earlybird VC | $21M | Oviva is a Switzerland-based digital health company founded in 2014 by Kai Eberhardt, Manuel Baumann, and others, specializing in technology-enabled therapy programs for Type 2 diabetes, obesity, and other weight-related conditions. Its platform combines a medical-device-certified app with remote multidisciplinary care teams including dietitians, psychologists, and clinicians to deliver personalized, evidence-based interventions. Patients are referred by general practitioners or health insurers primarily in the UK, Germany, and Switzerland, with programs fully reimbursed by public health systems. Oviva's approach emphasizes behavior change as a cost-effective method for managing diet-related conditions, improving patient compliance and outcomes while reducing costs for health systems. Executives highlighted the potential to transform access to effective treatments, with digital solutions showing superior results compared to traditional care. On January 15, 2020, Oviva raised $21 million in a Series B funding round led by MTIP AG, with participation from new investor Earlybird Venture Capital and existing investors AlbionVC, F-Prime Capital, Eight Roads Ventures, and Partech. This brought the company's total funding to $34 million at that point. MTIP's Christoph Kausch and Earlybird's Rainer Christine joined Oviva's board. The capital was earmarked to develop Oviva's technology further and expand across Europe to reach millions of underserved patients with diabetes and obesity management solutions. Later developments include a much larger Series D round in January 2026, raising approximately $200-220 million led by Kinnevik, with participation from Planet First Partners, A.P. Moller Holding, Lunate, EGS Beteiligungen AG, Norrsken VC, Temasek, and Sofina. By then, Oviva had supported over one million patients, tripled new patient intake in recent years, and achieved cash-flow profitability in 2025, planning expansions into hypertension, type 2 diabetes, and AI enhancements. |
| Nov 2017 | Series A | Partech; F-Prime; Walking Ventures; Eight Roads Ventures; AlbionVC | $12M | - |
Who has invested in Oviva?
15 investors have backed Oviva across its funding rounds, including F-Prime, Eight Roads Ventures, AlbionVC, Sofina, Partech and Earlybird VC.
Lead investors include Kinnevik, Sofina, Temasek and MTIP AG.
Oviva Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 3 | Participant | Nov 2017 | ||
| 3 | Participant | Nov 2017 | ||
| 3 | Participant | Nov 2017 | ||
| 3 | Lead | Aug 2021 | ||
| 2 | Lead | Jan 2020 | ||
| 2 | Participant | Jan 2026 | ||
| 2 | Participant | Nov 2017 | ||
| 2 | Participant | Jan 2026 | ||
| 2 | Participant | Jan 2026 | ||
| 2 | Lead | Jan 2026 | ||
| 2 | Participant | Jan 2020 | ||
| 2 | Participant | Jan 2026 | ||
| 2 | Participant | Jan 2026 | ||
This data is available for Pro users. Sign up to see all 15 Oviva investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialOviva Competitors
Oviva competitors include listed companies like Nyxoah and Kooth, and private ones like Ro, Sword Health, Noom and Pristyn Care.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | $598M | - | $7B | 11.7x | ||
| Private | $240M | - | $4B | 16.7x | ||
| Private | $400M | - | $3.7B | 9.3x | ||
| Private | $64M | - | $1.4B | - | ||
| Publicly listed | $12M | ($97M) | $158M | 3.1x | ||
| Publicly listed | $85M | $13M | $91M | 0.7x |
Oviva Public Comps
Oviva is still privately-owned, but its public comps include Max Healthcare Institute, Oscar Health, Hims, Compass Pathways, Alignment Healthcare, Ping An Healthcare, JMDC, GoodRx, Teladoc and Helus Pharma.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $858M | $232M | 12.8x | 10.4x | 47.5x | 37.5x | |||
| $12B | ($391M) | 0.5x | 0.4x | (16.1x) | 12.6x | |||
| $2.3B | $178M | 3.1x | 2.4x | 40.6x | 24.0x | |||
| - | ($293M) | - | - | (5.9x) | (8.6x) | |||
| $3.9B | $45M | 0.3x | 0.3x | 30.0x | 9.5x | |||
| $816M | $52M | 0.9x | 1.0x | 14.3x | 18.0x | |||
| $322M | $88M | 5.0x | 4.6x | 18.4x | 17.8x | |||
| $797M | $173M | 1.8x | 1.7x | 8.0x | 5.5x | |||
This data is available for Pro users. Sign up to see all Oviva competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Oviva
| When was Oviva founded? | Oviva was founded in 2013. |
| Where is Oviva headquartered? | Oviva is headquartered in Zurich, Switzerland. |
| Is Oviva publicly listed? | No, Oviva is a private, VC-backed company. |
| How much funding has Oviva raised? | Oviva has raised $350M across 4 funding rounds. |
| What was Oviva's last funding round? | Oviva's last funding round was a $237M Series D in January 2026, led by Kinnevik. |
| Who are Oviva's investors? | Oviva's investors include F-Prime, Eight Roads Ventures, AlbionVC, Sofina, MTIP AG, EGS Beteiligungen, Partech, Norrsken VC, Planet First Partners, Kinnevik and 5 others. |
| Which companies are comparable to Oviva? | Companies comparable to Oviva include Ro, Sword Health, Noom, Pristyn Care, Nyxoah and Kooth. |
See companies similar to Oviva
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




